Cargando…
Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer
Adjuvant endocrine therapy (AET) is recommended after hormone receptor-positive breast cancer to reduce risk of recurrence, but adherence is sub-optimal in many women. Behavioral interventions have been ineffective in improving adherence rates to AET. This qualitative descriptive study investigates...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293219/ https://www.ncbi.nlm.nih.gov/pubmed/34287250 http://dx.doi.org/10.3390/curroncol28040227 |
_version_ | 1783724987225473024 |
---|---|
author | Toivonen, Kirsti I. Oberoi, Devesh King-Shier, Kathryn Piedalue, Katherine-Ann L. Rash, Joshua A. Carlson, Linda E. Campbell, Tavis S. |
author_facet | Toivonen, Kirsti I. Oberoi, Devesh King-Shier, Kathryn Piedalue, Katherine-Ann L. Rash, Joshua A. Carlson, Linda E. Campbell, Tavis S. |
author_sort | Toivonen, Kirsti I. |
collection | PubMed |
description | Adjuvant endocrine therapy (AET) is recommended after hormone receptor-positive breast cancer to reduce risk of recurrence, but adherence is sub-optimal in many women. Behavioral interventions have been ineffective in improving adherence rates to AET. This qualitative descriptive study investigates factors that support women in AET use and suggestions for interventions to improve AET use and management. Interviews with women who persisted with AET (n = 23), women who discontinued AET (n = 15), and healthcare providers (HCPs; oncologists, oncology residents, and pharmacists; n = 9) were conducted, transcribed, and described using thematic analysis. Data collection stopped once saturation occurred (i.e., no new codes or themes emerged during interviews). Two researchers created codes and developed themes in an iterative process; a third researcher verified the representativeness of final themes. This study was approved by the Health Research Ethics Board of Alberta (ID: HREBA.CC-17-0513). Women who persisted described being prepared for side effects and having self-management strategies, strong rationale for AET use, supportive HCPs, and available resources as relevant factors. Women who discontinued described feeling overwhelmed by side effects, information needs, drawbacks of AET, helpful/unhelpful experiences with HCPs, and contextual factors as relevant to their discontinuation. HCPs described health system-related and patient-related barriers, side effect management, and patient-provider interactions as relevant to supporting AET use. The considerable overlap in themes among the three groups suggests broad recognition of salient factors relevant to AET use and that associated strategies to improve use may be acceptable to patients and providers alike. Factors supporting AET use could include the following: education (which may be necessary but insufficient), developing a strong personal rationale for use, being prepared for side effects, having side effect management strategies, reciprocal communication between patients and HCPs, and accessible resources. |
format | Online Article Text |
id | pubmed-8293219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82932192021-07-22 Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer Toivonen, Kirsti I. Oberoi, Devesh King-Shier, Kathryn Piedalue, Katherine-Ann L. Rash, Joshua A. Carlson, Linda E. Campbell, Tavis S. Curr Oncol Article Adjuvant endocrine therapy (AET) is recommended after hormone receptor-positive breast cancer to reduce risk of recurrence, but adherence is sub-optimal in many women. Behavioral interventions have been ineffective in improving adherence rates to AET. This qualitative descriptive study investigates factors that support women in AET use and suggestions for interventions to improve AET use and management. Interviews with women who persisted with AET (n = 23), women who discontinued AET (n = 15), and healthcare providers (HCPs; oncologists, oncology residents, and pharmacists; n = 9) were conducted, transcribed, and described using thematic analysis. Data collection stopped once saturation occurred (i.e., no new codes or themes emerged during interviews). Two researchers created codes and developed themes in an iterative process; a third researcher verified the representativeness of final themes. This study was approved by the Health Research Ethics Board of Alberta (ID: HREBA.CC-17-0513). Women who persisted described being prepared for side effects and having self-management strategies, strong rationale for AET use, supportive HCPs, and available resources as relevant factors. Women who discontinued described feeling overwhelmed by side effects, information needs, drawbacks of AET, helpful/unhelpful experiences with HCPs, and contextual factors as relevant to their discontinuation. HCPs described health system-related and patient-related barriers, side effect management, and patient-provider interactions as relevant to supporting AET use. The considerable overlap in themes among the three groups suggests broad recognition of salient factors relevant to AET use and that associated strategies to improve use may be acceptable to patients and providers alike. Factors supporting AET use could include the following: education (which may be necessary but insufficient), developing a strong personal rationale for use, being prepared for side effects, having side effect management strategies, reciprocal communication between patients and HCPs, and accessible resources. MDPI 2021-07-05 /pmc/articles/PMC8293219/ /pubmed/34287250 http://dx.doi.org/10.3390/curroncol28040227 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Toivonen, Kirsti I. Oberoi, Devesh King-Shier, Kathryn Piedalue, Katherine-Ann L. Rash, Joshua A. Carlson, Linda E. Campbell, Tavis S. Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer |
title | Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer |
title_full | Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer |
title_fullStr | Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer |
title_full_unstemmed | Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer |
title_short | Both “Vitamin L for Life” and “One Milligram of Satan”: A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer |
title_sort | both “vitamin l for life” and “one milligram of satan”: a multi-perspective qualitative exploration of adjuvant endocrine therapy use after breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293219/ https://www.ncbi.nlm.nih.gov/pubmed/34287250 http://dx.doi.org/10.3390/curroncol28040227 |
work_keys_str_mv | AT toivonenkirstii bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer AT oberoidevesh bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer AT kingshierkathryn bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer AT piedaluekatherineannl bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer AT rashjoshuaa bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer AT carlsonlindae bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer AT campbelltaviss bothvitaminlforlifeandonemilligramofsatanamultiperspectivequalitativeexplorationofadjuvantendocrinetherapyuseafterbreastcancer |